Amniotics AB (publ)

As of December 31, 2023, Amniotics AB (publ) has 2.71B shares outstanding.

These figures are as of December 31, 2023.

As of December 31, 2023, Amniotics AB (publ) maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -113.20, reflecting losses generated across the asset base.

As of the close on September 27, 2024, Amniotics AB (publ)'s stock has declined approximately 89.16% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

These figures cover the twelve months ended December 31, 2023. Free cash flow yield is negative at -519.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6,117.31, meaning Amniotics AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Amniotics AB (publ)'s most recent stock split took place on October 6, 2023 with a 200:681 split ratio.

As of December 31, 2023, Amniotics AB (publ) has an Altman Z-Score of -12.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.